<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680242</article-id><article-id pub-id-type="doi">10.3390/v16121836</article-id><article-id pub-id-type="publisher-id">viruses-16-01836</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Characterization and Fluctuations of an Ivermectin Binding Site at the Lipid Raft Interface of the N-Terminal Domain (NTD) of the Spike Protein of SARS-CoV-2 Variants</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lefebvre</surname><given-names>Marine</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-16-01836" ref-type="aff">1</xref><xref rid="af2-viruses-16-01836" ref-type="aff">2</xref><xref rid="af3-viruses-16-01836" ref-type="aff">3</xref><xref rid="af4-viruses-16-01836" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9516-4168</contrib-id><name><surname>Chahinian</surname><given-names>Henri</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-viruses-16-01836" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8006-7704</contrib-id><name><surname>La Scola</surname><given-names>Bernard</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01836" ref-type="aff">1</xref><xref rid="af2-viruses-16-01836" ref-type="aff">2</xref><xref rid="af3-viruses-16-01836" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8653-5521</contrib-id><name><surname>Fantini</surname><given-names>Jacques</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af4-viruses-16-01836" ref-type="aff">4</xref><xref rid="c1-viruses-16-01836" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Harty</surname><given-names>Ronald N.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01836"><label>1</label>IHU M&#x000e9;diterran&#x000e9;e Infection, 19-21 Boulevard Jean Moulin, 13005 Marseille, France; <email>marinelfv@gmail.com</email> (M.L.); <email>bernard.la-scola@univ-amu.fr</email> (B.L.S.)</aff><aff id="af2-viruses-16-01836"><label>2</label>Microbes Evolution Phylogeny and Infections (MEPHI), Aix-Marseille Universit&#x000e9;, 27 Boulevard Jean Moulin, 13005 Marseille, France</aff><aff id="af3-viruses-16-01836"><label>3</label>Assistance Publique-H&#x000f4;pitaux de Marseille (AP-HM), 264 Rue Saint-Pierre, 13005 Marseille, France</aff><aff id="af4-viruses-16-01836"><label>4</label>Department of Biology, Faculty of Medicine, Aix-Marseille University, INSERM UA16, 13015 Marseille, France; <email>henrichahinian@gmail.com</email></aff><author-notes><corresp id="c1-viruses-16-01836"><label>*</label>Correspondence: <email>jacques.fantini@univ-amu.fr</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1836</elocation-id><history><date date-type="received"><day>14</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>08</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Most studies on the docking of ivermectin on the spike protein of SARS-CoV-2 concern the receptor binding domain (RBD) and, more precisely, the RBD interface recognized by the ACE2 receptor. The N-terminal domain (NTD), which controls the initial attachment of the virus to lipid raft gangliosides, has not received the attention it deserves. In this study, we combined molecular modeling and physicochemical approaches to analyze the mode of interaction of ivermectin with the interface of the NTD-facing lipid rafts of the host cell membrane. We characterize a binding area that presents point mutations and deletions in successive SARS-CoV-2 variants from the initial strain to omicron KP.3 circulating in many countries in 2024. We show that ivermectin has exceptional flexibility, allowing the drug to bind to the spike protein of all variants tested. The energy of interaction is specific to each variant, allowing a classification according to their affinity for ivermectin in the following ascending order: Omicron KP.3 &#x0003c; Delta &#x0003c; Omicron BA.5 &#x0003c; Alpha &#x0003c; Wuhan (B.1) &#x0003c; Omicron BA.1. The binding site of ivermectin is subject to important variations of the NTD, including the Y144 deletion. It overlaps with the ganglioside binding domain of the NTD, as demonstrated by docking and physicochemical studies. These results suggest a new mechanism of antiviral action for ivermectin based on competitive inhibition for initial virus attachment to lipid rafts. The current KP.3 variant is still recognized by ivermectin, although with an affinity slightly lower than the Wuhan strain.</p></abstract><kwd-group><kwd>ivermectin</kwd><kwd>antiviral</kwd><kwd>SARS-CoV-2</kwd><kwd>ganglioside</kwd><kwd>lipid raft</kwd><kwd>docking</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01836"><title>1. Introduction</title><p>Understanding the infection mechanisms of RNA viruses is essential for developing effective vaccine and therapeutic strategies. Typically, research in virology focuses on identifying host cell plasma membrane proteins that act as receptors for these viruses. Thus, CD4 has been identified as the main receptor for HIV-1 [<xref rid="B1-viruses-16-01836" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01836" ref-type="bibr">2</xref>] and ACE2 that of SARS-CoV-2 [<xref rid="B3-viruses-16-01836" ref-type="bibr">3</xref>]. This conception, widely shared by most virologists on the planet, however, ignores the fact that before interacting with a specific receptor, the virus must first be attracted by the cell and attach to its surface [<xref rid="B4-viruses-16-01836" ref-type="bibr">4</xref>]. This step, which is the earliest in the infection cycle of RNA viruses, is generally bypassed in virus&#x02013;host interaction studies. Thus, vaccine and therapeutic approaches remain focused on inhibiting the interaction between the virus and its receptor, either by antibodies (active or passive immunotherapy) or by molecules that are often repositioned when they prove to have an inhibitory effect on virus&#x02013;receptor interactions. The initial interaction of an RNA virus with the host cell relies chiefly on an electrostatic attraction between the viral envelope proteins and lipid rafts present at the cell surface [<xref rid="B5-viruses-16-01836" ref-type="bibr">5</xref>]. Due to their richness in gangliosides possessing negatively charged sialic acids, these rafts offer an electronegative landing platform for viruses whose envelope proteins have cationic zones [<xref rid="B6-viruses-16-01836" ref-type="bibr">6</xref>]. The virus&#x02013;membrane interaction can then be broken down into two steps according to the dual receptor model proposed thirty years ago by N. Yahi and J. Fantini for HIV-1 and, more recently, for SARS-CoV-2 [<xref rid="B7-viruses-16-01836" ref-type="bibr">7</xref>]. In this model, the virus recognizes two distinct receptors, the raft gangliosides and a protein receptor. The cooperation of these two types of receptors then allows optimal adhesion of the virus to the surface of the host cell. The dual interaction is mediated by two distinct domains of the virus adhesion protein, thus allowing the formation of a ganglioside&#x02013;virus&#x02013;protein ternary complex [<xref rid="B8-viruses-16-01836" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01836" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01836" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01836" ref-type="bibr">11</xref>]. The SARS-CoV-2 spike protein recognizes raft gangliosides by its N-terminal domain (NTD), whose flat surface has clearly been optimized during the evolution of this coronavirus and its probable passage through different animal hosts [<xref rid="B11-viruses-16-01836" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01836" ref-type="bibr">12</xref>]. The ACE2 receptor is recognized by another region of the spike protein called the receptor binding domain (RBD) [<xref rid="B13-viruses-16-01836" ref-type="bibr">13</xref>]. A key point of this mechanism is that the ganglioside binding domain of the NTD is immediately accessible, while the RBD remains cryptic until the virus lands on a raft. It is, therefore, crucial to develop therapeutic and vaccine approaches targeting the ganglioside binding domain of the NTD to block the initial attachment of the virus to the surface of the host cell. The immune response is generated by such antibodies that have a strong neutralizing power [<xref rid="B14-viruses-16-01836" ref-type="bibr">14</xref>,<xref rid="B15-viruses-16-01836" ref-type="bibr">15</xref>,<xref rid="B16-viruses-16-01836" ref-type="bibr">16</xref>]. At the therapeutic level, we have previously shown that azithromycin binds to the ganglioside binding domain of the NTD of the spike protein (Wuhan B.1 strain) [<xref rid="B17-viruses-16-01836" ref-type="bibr">17</xref>], which may legitimize its interest in anti-COVID-19 therapy, alone or in combination with other antivirals [<xref rid="B18-viruses-16-01836" ref-type="bibr">18</xref>,<xref rid="B19-viruses-16-01836" ref-type="bibr">19</xref>]. In this new study, which combines in silico and physicochemical approaches, we show that ivermectin, which is part of the therapeutic arsenal repositioned as an antiviral [<xref rid="B20-viruses-16-01836" ref-type="bibr">20</xref>,<xref rid="B21-viruses-16-01836" ref-type="bibr">21</xref>], recognizes the ganglioside binding domain of successive SARS-CoV-2 variants from the Wuhan B.1 strain to the KP.2/KP.3 variants [<xref rid="B22-viruses-16-01836" ref-type="bibr">22</xref>,<xref rid="B23-viruses-16-01836" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01836" ref-type="bibr">24</xref>,<xref rid="B25-viruses-16-01836" ref-type="bibr">25</xref>] circulating in 2024. We characterize its binding site on the NTD of the different variants, and we demonstrate that its conformational flexibility allows it to adapt to all these variants.</p></sec><sec id="sec2-viruses-16-01836"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01836"><title>2.1. Materials</title><p>Ivermectin was supplied by Sigma Aldrich (St. Quentin Fallavier, France). The stock solution was diluted in 2.5% DMSO and 97.5% water. Full-length trimeric recombinant spike proteins (BioServUK, Sheffield, UK) of four SARS-CoV-2 strains were used in this study: Wuhan, Alpha, Delta, and Omicron BA.1 (BSV-COV-PR-33, BSV-COV-PR-65, BSV-COV-PR-97, and BSV-COV-OM-0.1, respectively). The spike protein of each viral strain was dissolved in PBS at a concentration of 2 nM and tested at a final concentration of 5 pM in the monolayer assay.</p></sec><sec id="sec2dot2-viruses-16-01836"><title>2.2. Molecular Modeling Simulations</title><p>In silico analyses were performed using the Hyperchem and Molegro Molecular Viewer as described previously [<xref rid="B10-viruses-16-01836" ref-type="bibr">10</xref>]. Interaction energies were calculated from stable complexes using the Ligand Energy Inspector function of Molegro. A complete structure of the reference spike protein was generated from pdb 7bnm, as previously described [<xref rid="B26-viruses-16-01836" ref-type="bibr">26</xref>]. All gaps in the pdb file were fixed by inserting the missing amino acids with the protein structure prediction service Robetta, <uri xlink:href="https://robetta.bakerlab.org/">https://robetta.bakerlab.org/</uri> (accessed on 10 August 2024) [<xref rid="B27-viruses-16-01836" ref-type="bibr">27</xref>]. This source file model was used to introduce the specific mutational profiles of the indicated Alpha, Delta, and Omicron variants with the MUTATE tool of the Swiss-Pdb Viewer [<xref rid="B28-viruses-16-01836" ref-type="bibr">28</xref>]. The trimeric structure in the closed pre-fusion conformation was constructed using the Swiss-Pdb Viewer by homology with a reference model (pdb: 6VSB). All structures were then submitted to several rounds of energy minimization with the Polak&#x02013;Ribi&#x000e8;re algorithm. The electrostatic surface potential was analyzed using the Molegro Molecular Viewer [<xref rid="B29-viruses-16-01836" ref-type="bibr">29</xref>]. The docking of ivermectin on the spike proteins was performed using Hyperchem [<xref rid="B30-viruses-16-01836" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01836" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01836" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01836" ref-type="bibr">33</xref>] as previously described [<xref rid="B17-viruses-16-01836" ref-type="bibr">17</xref>]. Several initial conditions were tested, and only those with the highest energy interaction after energy minimization with the Polak&#x02013;Ribi&#x000e8;re algorithm were selected. The energy of interaction of each molecular complex was calculated using the Ligand Energy Inspector tool of the Molegro Molecular Viewer [<xref rid="B34-viruses-16-01836" ref-type="bibr">34</xref>]. A detailed description of our flexible docking method, compared with other approaches, is provided at the beginning of <xref rid="sec3-viruses-16-01836" ref-type="sec">Section 3</xref>.</p></sec><sec id="sec2dot3-viruses-16-01836"><title>2.3. Langmuir Microtensiometry</title><p>Surface pressure measurements were performed using the Langmuir film balance technique with a fully automated microtensiometer (&#x000b5;TROUGH SX, Kibron Inc., Helsinki, Finland). The interaction of a peptide (or a protein) with a ganglioside monolayer is an interfacial phenomenon that can be studied by surface pressure (&#x003c0;) measurements [<xref rid="B35-viruses-16-01836" ref-type="bibr">35</xref>,<xref rid="B36-viruses-16-01836" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01836" ref-type="bibr">37</xref>]. The interaction of a protein with a ganglioside lipid monolayer can be detected at a constant area by an increase in the surface pressure (&#x00394;&#x003c0;). This increase is caused by the insertion of the protein between the polar heads of vicinal gangliosides, which is not counterbalanced by an increase in the area of the monolayer. This effect can be followed kinetically by real-time surface pressure measurements after injecting the protein into the aqueous subphase underneath the ganglioside monolayer, as described previously [<xref rid="B38-viruses-16-01836" ref-type="bibr">38</xref>]. The initial velocity of the insertion process is expressed as mN&#x000b7;m<sup>&#x02212;1</sup>&#x000b7;min<sup>&#x02212;1</sup>. All experiments were conducted at 20 &#x000b0;C in triplicate. To test the inhibitory effect of ivermectin, the drug was preincubated with the spike proteins for 30 min at room temperature before injection underneath the ganglioside monolayer.</p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01836"><title>3. Results</title><sec id="sec3dot1-viruses-16-01836"><title>3.1. Flexible Docking Analysis</title><p>Due to the rapid development of artificial intelligence (AI) these last years, molecular docking can now be used by researchers who may not have any prior experience in this field, whatever their background in structural biochemistry. In this case, step-by-step procedures are available, allowing anybody to generate and download ligand&#x02013;protein complexes at the atomic scale [<xref rid="B39-viruses-16-01836" ref-type="bibr">39</xref>]. However, the automatic docking methods offered by software such as Dock [<xref rid="B40-viruses-16-01836" ref-type="bibr">40</xref>] or Autodock [<xref rid="B41-viruses-16-01836" ref-type="bibr">41</xref>] suffer from significant limitations which can generate artifacts that can partially or even completely call into question the results obtained [<xref rid="B42-viruses-16-01836" ref-type="bibr">42</xref>,<xref rid="B43-viruses-16-01836" ref-type="bibr">43</xref>,<xref rid="B44-viruses-16-01836" ref-type="bibr">44</xref>,<xref rid="B45-viruses-16-01836" ref-type="bibr">45</xref>]. Thus, one of the critical elements of molecular docking is taking into account the flexibility of proteins at the level of amino acid side chains but also at the level of their three-dimensional structure, in particular when loops with no stable structure are involved in the ligand binding site [<xref rid="B46-viruses-16-01836" ref-type="bibr">46</xref>]. Often, this site does not pre-exist on the protein and is gradually created during the interaction with the ligand, according to an induced fit process widely described in the literature [<xref rid="B47-viruses-16-01836" ref-type="bibr">47</xref>,<xref rid="B48-viruses-16-01836" ref-type="bibr">48</xref>,<xref rid="B49-viruses-16-01836" ref-type="bibr">49</xref>,<xref rid="B50-viruses-16-01836" ref-type="bibr">50</xref>], as is the case for intrinsically disordered proteins (IDPs) [<xref rid="B51-viruses-16-01836" ref-type="bibr">51</xref>,<xref rid="B52-viruses-16-01836" ref-type="bibr">52</xref>,<xref rid="B53-viruses-16-01836" ref-type="bibr">53</xref>]. It is, therefore, crucial to validate the docking results a posteriori by molecular dynamics (MD) or molecular mechanics (MM) simulations, which follow the evolution of a protein&#x02013;ligand complex obtained by automatic docking [<xref rid="B43-viruses-16-01836" ref-type="bibr">43</xref>,<xref rid="B54-viruses-16-01836" ref-type="bibr">54</xref>,<xref rid="B55-viruses-16-01836" ref-type="bibr">55</xref>,<xref rid="B56-viruses-16-01836" ref-type="bibr">56</xref>,<xref rid="B57-viruses-16-01836" ref-type="bibr">57</xref>,<xref rid="B58-viruses-16-01836" ref-type="bibr">58</xref>]. Thus, many studies are carried out according to a two-step protocol, starting with a molecular docking study and followed by MD or MM simulations. This approach allows us to validate or invalidate the docking results by following the protein&#x02013;ligand complex evolution over time [<xref rid="B43-viruses-16-01836" ref-type="bibr">43</xref>]. The simulation time then becomes a new critical parameter of the method. In 30 years, it has gone from a few picoseconds to a hundred nanoseconds, and simplifications such as coarse grain now make it possible to reach the millisecond scale for complex systems, including, for example, a cell membrane [<xref rid="B59-viruses-16-01836" ref-type="bibr">59</xref>,<xref rid="B60-viruses-16-01836" ref-type="bibr">60</xref>,<xref rid="B61-viruses-16-01836" ref-type="bibr">61</xref>,<xref rid="B62-viruses-16-01836" ref-type="bibr">62</xref>].</p><p>The strategy that we have developed for many years in our team is different. Rather than using rigid docking conditions (protein and ligand immobilized in starting structures that do not evolve during the simulation) or semi-flexible (taking into account the conformational freedom of the amino acid side chains on a fixed secondary structure), our approach takes into account the conformational flexibility of the protein and the ligand without a priori. The simulation is carried out using the Polak&#x02013;Ribi&#x000e8;re conjugate gradient method [<xref rid="B63-viruses-16-01836" ref-type="bibr">63</xref>,<xref rid="B64-viruses-16-01836" ref-type="bibr">64</xref>,<xref rid="B65-viruses-16-01836" ref-type="bibr">65</xref>,<xref rid="B66-viruses-16-01836" ref-type="bibr">66</xref>], which allows the energy minimizations of the two partners to be obtained before the interaction and throughout the binding process [<xref rid="B38-viruses-16-01836" ref-type="bibr">38</xref>,<xref rid="B67-viruses-16-01836" ref-type="bibr">67</xref>]. The flexibility of the ligand and its adaptation to its binding site obey dynamic molecular mechanisms that are fully considered by our method. This approach allows for the combination of docking, flexibility of the protein and the ligand, and evolution of the complex as a function of time until stable conditions are reached. The computation time, although faster than MM and especially MD simulations, remains high for systems with several thousand atoms, such as those analyzed in the present study [<xref rid="B68-viruses-16-01836" ref-type="bibr">68</xref>]. The Polak&#x02013;Ribi&#x000e8;re energy minimization is an iteration of cycles until the system reaches a root-mean-square (RMS) gradient of 0.1 kcal&#x000b7; &#x000c5;<sup>&#x02212;1</sup>&#x000b7;mol<sup>&#x02212;1</sup> as the convergence condition. The robustness of the complex can then be confirmed by further lowering this threshold, which we performed in our docking study of ivermectin on the spike protein of SARS-CoV-2 variants (convergence condition of 0.01 kcal&#x000b7; &#x000c5;<sup>&#x02212;1</sup>&#x000b7;mol<sup>&#x02212;1</sup>).</p></sec><sec id="sec3dot2-viruses-16-01836"><title>3.2. Mutational Landscape of the Spike Protein from the Original B.1 Strain to KP.3</title><p>The evolution of the spike protein from the original B.1 strain to the KP.3 variant circulating in 2024 is characterized by a progressive accumulation of mutations and indels (insertions/deletions) (<xref rid="viruses-16-01836-f001" ref-type="fig">Figure 1</xref>). Despite this accumulation of mutations in the NTD and RBD functional domains, culminating in the omicron series variants, the virus maintained its ability to bind to raft gangliosides and to the ACE2 receptor. However, this large structural variability requires specific studies for each variant. We, therefore, began by searching for a potential ivermectin site on the NTD of strain B.1, and then we studied the evolution of this site on the alpha, delta, and omicron variants shown in <xref rid="viruses-16-01836-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec3dot3-viruses-16-01836"><title>3.3. Characterization of an Ivermectin Binding Site in the NTD of the B.1 Spike Protein</title><p>Our molecular modeling studies have previously identified a binding site for raft gangliosides at the top of the NTD in a large flat area. Here, we present a new docking study for ivermectin, based on the same molecular modeling principles with minimized spike protein structures extracted from the Protein DataBank files and completed for all gaps. This allowed us to identify an ivermectin binding site also located on the NTD surface (<xref rid="viruses-16-01836-f002" ref-type="fig">Figure 2</xref>).</p><p>The total energy of interaction between ivermectin and the B.1 NTD complex is &#x02212;129.5 kJ&#x000b7;mol<sup>&#x02212;1</sup> (<xref rid="viruses-16-01836-t001" ref-type="table">Table 1</xref>). The trimeric spike protein has three NTDs, and it can thus accommodate three ivermectin molecules simultaneously.</p><p>The models in <xref rid="viruses-16-01836-f003" ref-type="fig">Figure 3</xref> illustrate the robustness of our docking method. The superposition of the spike protein structure before and after docking shows significant differences in the secondary structure (<xref rid="viruses-16-01836-f003" ref-type="fig">Figure 3</xref>A,B) and in the side chains interacting with the ligand (R158) or much more distant (F140) (<xref rid="viruses-16-01836-f003" ref-type="fig">Figure 3</xref>C), which indicates a good consideration of long-range conformational changes that are generally ignored by classical automatic docking techniques.</p><p><xref rid="app1-viruses-16-01836" ref-type="app">Figure S1</xref> shows the evolution of the complex formed by a spike protein and ivermectin. This animation shows the movements of the entire protein (including the RBD) during the interaction with the ligand, which perfectly illustrates our all-atom flexible docking method.</p></sec><sec id="sec3dot4-viruses-16-01836"><title>3.4. The Ivermectin Binding Site Occupies a Large Part of the GM1-Binding Domain of the NTD</title><p>We have previously published the molecular characteristics of the interaction between a GM1 ganglioside raft and the isolated NTD of the spike protein [<xref rid="B17-viruses-16-01836" ref-type="bibr">17</xref>]. In the present article, we studied the interaction of a similar GM1 raft with the NTD of the entire spike protein. This new simulation allowed us to clarify how the spike protein interacts with the GM1 ganglioside cluster and to compare the results with the spike&#x02013;ivermectin docking (<xref rid="viruses-16-01836-f004" ref-type="fig">Figure 4</xref>). It appears that ivermectin occupies a significant part of the raft binding site. Many amino acids participate in both complexes, including Q14, E156, R158, G252, D253, and R246. These results strongly suggest that ivermectin can act as a competitive inhibitor of the raft&#x02013;NTD interaction.</p></sec><sec id="sec3dot5-viruses-16-01836"><title>3.5. Structural Variations of the Ivermectin Binding Site in the NTD of SARS-CoV-2 Variants</title><p>In the second step, we analyzed the interaction of ivermectin with the different variants of SARS-CoV-2 (<xref rid="viruses-16-01836-f005" ref-type="fig">Figure 5</xref>). Despite significant structural variations due to the accumulation of mutations and indels in the NTD, it appears that ivermectin is able to bind to all variants. However, the modalities of this interaction vary greatly depending on the variants, which affects the affinity of ivermectin (<xref rid="viruses-16-01836-t001" ref-type="table">Table 1</xref>).</p><p>A complete analysis of the interaction modalities of ivermectin with the different spike proteins is presented in <xref rid="viruses-16-01836-t001" ref-type="table">Table 1</xref>. It emerges from this analysis that ivermectin has surprising adaptive capacities in regard to the evolution of spike proteins. Thus, the amino acids involved in the interaction vary for each complex, both in terms of their absence or presence on the site but also in terms of the interaction energy of each amino acid. For instance, R19 appears only in the complex with the NTD of the Delta variant. Y144 is involved in the binding of ivermectin to Wuhan and Delta spikes. S254 is important for the binding of ivermectin to the NTD of Omicron BA.1 and BA.5 variants. Four amino acids are significantly involved in the interaction of ivermectin with all variants: Q14, V16, N17, and D253, with various values of the energy of interaction.</p><table-wrap position="anchor" id="viruses-16-01836-t001"><object-id pub-id-type="pii">viruses-16-01836-t001_Table 1</object-id><label>Table 1</label><caption><p>Evolution of ivermectin binding site in the NTD of SARS-CoV-2 variant spike proteins.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Amino Acid</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Wuhan <break/>B.1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Alpha<break/>B.1.1.7</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Delta<break/>B.1.617.2</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Omicron BA.1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Omicron BA.5</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Omicron KP.3</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Q14</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;13.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;19.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;19.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;13.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>C15</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;9.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>V16</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;19.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;15.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;17.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;16.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;16.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;18.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>N17</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>R19</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Y144</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;11.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>H146</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>K147</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;20.8</td><td align="center" valign="middle" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;8.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>E156</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;9.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;12.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;12.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;11.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>R158</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;13.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>R246</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(-)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;16.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;16.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>G252</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;6.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;1.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>D253</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;29.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;23.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;28.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;25.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;25.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;17.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>S254</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;18.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;18.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>S255</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;4.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;8.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;129.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;125.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;107.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;159.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;121.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;101.5</td></tr></tbody></table><table-wrap-foot><fn><p>Energy values are calculated from molecular models of ivermectin bound to the indicated spike protein in <xref rid="viruses-16-01836-f002" ref-type="fig">Figure 2</xref> and <xref rid="viruses-16-01836-f005" ref-type="fig">Figure 5</xref> and expressed as &#x00394;G in kJ&#x000b7;mol<sup>&#x02212;1</sup>. For the sake of clarity, only amino acids contributing more than 5 kJ&#x000b7;mol<sup>&#x02212;1</sup> in absolute value are mentioned, except when the concerned amino acid has a &#x00394;G &#x0003e; 5 kJ&#x000b7;mol<sup>&#x02212;1</sup> for another variant. (-) indicates that the amino acid is not involved in ivermectin binding (either because it is deleted in the corresponding variant or because it is expressed but does not belong to the ivermectin binding site).</p></fn></table-wrap-foot></table-wrap><p>This structural analysis, therefore, makes it possible to classify the different variants according to their affinity for ivermectin in the following ascending order: Omicron KP.3 &#x0003c; Delta &#x0003c; Omicron BA.5 &#x0003c; Alpha &#x0003c; Wuhan (B.1) &#x0003c; Omicron BA.1. What is striking about this classification is that it does not absolutely follow the chronological order of appearance of the variants. The NTD of the original Wuhan strain (B.1) is in the high part of the ranking, with an interaction energy of &#x02212;129.5 kJ&#x000b7;mol<sup>&#x02212;1</sup>. The highest affinity is reached by Omicron BA.1 (&#x02212;159.4 kJ&#x000b7;mol<sup>&#x02212;1</sup>), the lowest by Omicron KP.3 (&#x02212;101.5 kJ&#x000b7;mol<sup>&#x02212;1</sup>). Regardless, there is a remarkable structural adaptation of ivermectin to the NTD of each variant. This can only be explained by the conformational flexibility of ivermectin, illustrated in <xref rid="viruses-16-01836-f006" ref-type="fig">Figure 6</xref>. These different conformations recall the movements of an octopus with a central head and lateral arms. This is particularly well illustrated in the animation of <xref rid="app1-viruses-16-01836" ref-type="app">Figure S2</xref>.</p></sec><sec id="sec3dot6-viruses-16-01836"><title>3.6. Ivermectin Inhibits the Binding of SARS-CoV-2 Spike Trimers to Gangliosides</title><p>To validate these in silico studies, we performed a physicochemical analysis of the interaction of the spike protein with the GM1 ganglioside monolayer. In these experiments, the trimeric recombinant spike protein of each variant is injected into the aqueous phase underneath the ganglioside monolayer. Its interaction with the gangliosides is monitored in real-time by surface pressure measurements (<xref rid="viruses-16-01836-f007" ref-type="fig">Figure 7</xref>), showing the interaction kinetics of the spike proteins B.1, Alpha, Delta, and Omicron BA.1 with the GM1 ganglioside monolayers.</p><p>The four spike proteins interacted well with GM1 but with different modalities that reflect their structural differences. The spikes of the Wuhan B.1 strain and the Alpha variant seem to interact directly with the GM1 monolayer without any latency. In contrast, the spikes of Delta and Omicron BA.1 first affect the surface pressure downward before it increases, as in the case of the other two spike proteins. Overall, these increases in surface pressure, with or without latency, unambiguously indicate an interaction with GM1, thus confirming the structural studies carried out in silico. Indeed, an irrelevant protein (rabbit IgG) tested in similar conditions underneath a GM1 monolayer did not induce any surface pressure change. In the second step, we preincubated the Wuhan B.1 and Alpha spike proteins with ivermectin and then measured the impact of this treatment on the initial velocity of the spike&#x02013;GM1 interaction. It is important to note that this experiment could not be performed with the Delta and Omicron BA.1 spikes due to the latency time observed with these two spike proteins. On the other hand, the initial speed of interaction is a critical parameter of viral infection; any drug capable of delaying this interaction could potentially block viral infection at its earliest stage. The results in <xref rid="viruses-16-01836-f007" ref-type="fig">Figure 7</xref> show that ivermectin is able to inhibit the spike&#x02013;GM1 interaction, in agreement with molecular docking studies that have identified an ivermectin binding site in the middle of the ganglioside binding domain of the NTD.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01836"><title>4. Discussion</title><p>Our team uses a molecular docking method that takes into account the flexibility of the protein and the ligand before and during the formation of the protein&#x02013;ligand complex. This approach eliminates the artifacts often encountered in automatic docking studies, which then require the implementation of computationally time-consuming simulations such as MDS or MMS. On many occasions, we have validated the predictions obtained by our method using experiments, in particular by introducing mutations into the protein that lower the interaction energy of the protein&#x02013;ligand complex [<xref rid="B69-viruses-16-01836" ref-type="bibr">69</xref>]. We have also subjected several of our docking results to MDS, thus obtaining a double validation of our method [<xref rid="B17-viruses-16-01836" ref-type="bibr">17</xref>]. Regarding ivermectin, it is worth noting an artifact encountered in automatic docking for molecules with rings. Automatic docking often considers these rings as aromatic structures, while ivermectin does not have any. Thus, the docking of ivermectin on the RBD domain of the spike protein can be carried out with an unrealistic planar structure of the ligand, which requires additional MDS simulations to relax the ivermectin molecule and allow it to adopt more realistic conformations [<xref rid="B70-viruses-16-01836" ref-type="bibr">70</xref>]. Our own search for an ivermectin binding site on the RBD of the spike protein confirmed the results obtained in this direction by another team [<xref rid="B71-viruses-16-01836" ref-type="bibr">71</xref>]. However, the interaction energy of the RBD&#x02013;ivermectin complex is lower than that of the NTD-IVM complex (<xref rid="app1-viruses-16-01836" ref-type="app">Figure S3</xref>). We therefore focused on the NTD, as this region has been previously shown to contain a sialic acid binding domain, which may confer ganglioside recognition [<xref rid="B8-viruses-16-01836" ref-type="bibr">8</xref>,<xref rid="B72-viruses-16-01836" ref-type="bibr">72</xref>]. The NTD also has the particularity of being immediately accessible on the surface of the spike protein trimers carried by the virus, whereas the RBD must be unmasked to interact with its ACE2 receptor in a typical dual receptor mechanism dependent on the initial NTD&#x02013;ganglioside interaction [<xref rid="B9-viruses-16-01836" ref-type="bibr">9</xref>,<xref rid="B73-viruses-16-01836" ref-type="bibr">73</xref>]. Finally, there are three IVM binding sites (one at each end of the NTD) on the trimer, which is compatible with the inhibitory effect of IVM on hemagglutination [<xref rid="B74-viruses-16-01836" ref-type="bibr">74</xref>]. Overall, it is clear that the NTD is a promising target for designing antibodies and small molecules able to hamper the SARS-CoV-2 attachment to host cells [<xref rid="B73-viruses-16-01836" ref-type="bibr">73</xref>].</p><p>In the present study, we identified a binding site for ivermectin at the surface of the NTD of the SARS-CoV-2 spike protein. This site was first characterized on the spike protein of the original Wuhan B.1 strain. The involvement of the amino acid Y144 could suggest that this site no longer existed in SARS-CoV-2 variants with the Y144 deletion, especially Alpha [<xref rid="B26-viruses-16-01836" ref-type="bibr">26</xref>] and Omicron BA.1 [<xref rid="B75-viruses-16-01836" ref-type="bibr">75</xref>]. Furthermore, it appears that these two spike proteins have found two distinct paths to reconstitute the ivermectin binding site since the measured interaction energies are different (in particular, note the respective contributions of Q14, R246 and S254 in <xref rid="viruses-16-01836-t001" ref-type="table">Table 1</xref>). It can be considered that the selection pressure that has allowed the preservation of a functional interaction with the raft gangliosides has also allowed the preservation of a good affinity for ivermectin. This is manifested by interaction energy with the current variant KP.3 (&#x02212;101.5 kJ&#x000b7;mol<sup>&#x02212;1</sup>) close (78%) to that of the original strain (&#x02212;129.5 kJ&#x000b7;mol<sup>&#x02212;1</sup>), despite the accumulation of 15 mutations and deletions in the NTD and more than 60 in the whole spike protein [<xref rid="B22-viruses-16-01836" ref-type="bibr">22</xref>]. In a previous study, we compared raft gangliosides to quicksand, in which the spike protein NTD engages and is then stabilized by a network of hydrogen bonds [<xref rid="B6-viruses-16-01836" ref-type="bibr">6</xref>]. This mechanism is possible because raft gangliosides have great conformational freedom, especially at the periphery of the rafts, which is a privileged place for interaction with many ligands [<xref rid="B76-viruses-16-01836" ref-type="bibr">76</xref>]. As for ivermectin, we find great flexibility inherent in the molecule itself, which allows it to adapt to the different spike proteins of the variants and mimic the quicksand effect of rafts. In this case, we can describe the ivermectin molecule as a very flexible structure that can deform in all directions of space like an octopus (<xref rid="viruses-16-01836-f006" ref-type="fig">Figure 6</xref> and <xref rid="app1-viruses-16-01836" ref-type="app">Figure S2</xref>). Incidentally, this mechanism is fundamentally opposed to the classical concept of the key and lock in molecular interactions [<xref rid="B77-viruses-16-01836" ref-type="bibr">77</xref>]. This exceptional flexibility may allow additional interactions of ivermectin with the RBD of SARS-CoV-2 [<xref rid="B71-viruses-16-01836" ref-type="bibr">71</xref>]. In this respect, conformational flexibility, which finely controls virus&#x02013;receptor interactions [<xref rid="B78-viruses-16-01836" ref-type="bibr">78</xref>,<xref rid="B79-viruses-16-01836" ref-type="bibr">79</xref>], is a critical issue that needs to be considered in docking studies of potential antiviral drugs [<xref rid="B80-viruses-16-01836" ref-type="bibr">80</xref>].</p><p>Our modeling results were complemented by physicochemical experiments demonstrating the interaction of trimeric recombinant spike proteins with ganglioside monolayers mimicking the raft surface exposed to virus NTDs. We could test the Wuhan, Alpha, Delta, and Omicron BA.1 spikes that are commercially available for experimental research. In the future, it will be interesting to test other recombinant spike proteins, such as KP.3. We were also able to test the effect of ivermectin on the interaction of the Wuhan and Alpha spike proteins with GM1 monolayers. In these two cases, which were chosen because they did not present any delay in the interaction kinetics (<xref rid="viruses-16-01836-f007" ref-type="fig">Figure 7</xref>), we demonstrated an inhibitory effect of ivermectin. These physicochemical studies validate the results obtained in silico because the site identified for ivermectin is right in the middle of the ganglioside binding domain of the NTD. In these experiments, the excess of ivermectin relative to the protein was 1600-fold. This may seem high, but on the one hand, this ratio is in line with the concentrations of ivermectin necessary to inhibit the hemagglutination induced by spike proteins [<xref rid="B74-viruses-16-01836" ref-type="bibr">74</xref>] and on the other hand, ivermectin is an amphipathic compound that is only really soluble below 300 nM. Above this threshold value, which corresponds to its critical micellar concentration, ivermectin forms micelles and other molecular aggregates whose biological activity remains undetermined. Finally, there are three ivermectin binding sites per trimeric spike, which further decreases the molecular drug/spike ratio to 533, and 200 if we consider only the monomeric ivermectin molecules in solution above a concentration of 300 nM. Thus, our results support the idea that ivermectin behaves as a competitive inhibitor of the attachment of spike protein trimers to raft gangliosides. This mechanism of action, identified for the first time, could explain the antiviral effects of ivermectin on SARS-CoV-2 infection [<xref rid="B81-viruses-16-01836" ref-type="bibr">81</xref>], and on the hemagglutination induced by the spike proteins of different SARS-CoV-2 variants [<xref rid="B74-viruses-16-01836" ref-type="bibr">74</xref>,<xref rid="B82-viruses-16-01836" ref-type="bibr">82</xref>,<xref rid="B83-viruses-16-01836" ref-type="bibr">83</xref>,<xref rid="B84-viruses-16-01836" ref-type="bibr">84</xref>]. In both cases, blocking the spike&#x02013;ganglioside interaction could explain the beneficial effects of ivermectin, which deserves further evaluation for the potential treatment of COVID-19 disease and related symptoms.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-16-01836"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/v16121836/s1">https://www.mdpi.com/article/10.3390/v16121836/s1</uri>; Figure S1: Evolution of the complex formed by a spike protein and ivermectin in flexible docking; Figure S2: Conformational flexibility of ivermectin; Figure S3: Docking of ivermectin on the receptor-binding domain (RBD) of the Wuhan spike protein.</p><supplementary-material id="viruses-16-01836-s001" position="float" content-type="local-data"><media xlink:href="viruses-16-01836-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, H.C., B.L.S., and J.F.; Formal analysis, M.L. and J.F.; Investigation, M.L., H.C., and J.F.; Methodology, M.L., H.C., and J.F.; Resources, B.L.S.; Supervision, J.F.; Writing&#x02014;original draft, J.F.; Writing&#x02014;review and editing, H.C. and B.L.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors on request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01836"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDougal</surname><given-names>J.S.</given-names></name>
<name><surname>Maddon</surname><given-names>P.J.</given-names></name>
<name><surname>Dalgleish</surname><given-names>A.G.</given-names></name>
<name><surname>Clapham</surname><given-names>P.R.</given-names></name>
<name><surname>Littman</surname><given-names>D.R.</given-names></name>
<name><surname>Godfrey</surname><given-names>M.</given-names></name>
<name><surname>Maddon</surname><given-names>D.E.</given-names></name>
<name><surname>Chess</surname><given-names>L.</given-names></name>
<name><surname>Weiss</surname><given-names>R.A.</given-names></name>
<name><surname>Axel</surname><given-names>R.</given-names></name>
</person-group><article-title>The T4 glycoprotein is a cell-surface receptor for the AIDS virus</article-title><source>Cold Spring Harb. Symp. Quant. Biol.</source><year>1986</year><volume>51</volume><issue-part>Pt 2</issue-part><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1101/SQB.1986.051.01.083</pub-id><pub-id pub-id-type="pmid">3495395</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01836"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klatzmann</surname><given-names>D.R.</given-names></name>
<name><surname>McDougal</surname><given-names>J.S.</given-names></name>
<name><surname>Maddon</surname><given-names>P.J.</given-names></name>
</person-group><article-title>The CD4 molecule and HIV infection</article-title><source>Immunodefic. Rev.</source><year>1990</year><volume>2</volume><fpage>43</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">1973616</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01836"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shang</surname><given-names>J.</given-names></name>
<name><surname>Ye</surname><given-names>G.</given-names></name>
<name><surname>Shi</surname><given-names>K.</given-names></name>
<name><surname>Wan</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>C.</given-names></name>
<name><surname>Aihara</surname><given-names>H.</given-names></name>
<name><surname>Geng</surname><given-names>Q.</given-names></name>
<name><surname>Auerbach</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
</person-group><article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id><pub-id pub-id-type="pmid">32225175</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01836"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maginnis</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Virus&#x02013;Receptor Interactions: The Key to Cellular Invasion</article-title><source>J. Mol. Biol.</source><year>2018</year><volume>430</volume><fpage>2590</fpage><lpage>2611</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2018.06.024</pub-id><pub-id pub-id-type="pmid">29924965</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01836"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Azzaz</surname><given-names>F.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
</person-group><article-title>Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>284</elocation-id><pub-id pub-id-type="doi">10.3390/v15020284</pub-id><pub-id pub-id-type="pmid">36851498</pub-id>
</element-citation></ref><ref id="B6-viruses-16-01836"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matveeva</surname><given-names>M.</given-names></name>
<name><surname>Lefebvre</surname><given-names>M.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
<name><surname>Fantini</surname><given-names>J.</given-names></name>
</person-group><article-title>Host membranes as drivers of virus evolution</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1854</elocation-id><pub-id pub-id-type="doi">10.3390/v15091854</pub-id><pub-id pub-id-type="pmid">37766261</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01836"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
</person-group><article-title>Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>1923</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24031923</pub-id><pub-id pub-id-type="pmid">36768244</pub-id>
</element-citation></ref><ref id="B8-viruses-16-01836"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Milanetti</surname><given-names>E.</given-names></name>
<name><surname>Miotto</surname><given-names>M.</given-names></name>
<name><surname>Di Rienzo</surname><given-names>L.</given-names></name>
<name><surname>Nagaraj</surname><given-names>M.</given-names></name>
<name><surname>Monti</surname><given-names>M.</given-names></name>
<name><surname>Golbek</surname><given-names>T.W.</given-names></name>
<name><surname>Gosti</surname><given-names>G.</given-names></name>
<name><surname>Roeters</surname><given-names>S.J.</given-names></name>
<name><surname>Weidner</surname><given-names>T.</given-names></name>
<name><surname>Otzen</surname><given-names>D.E.</given-names></name>
</person-group><article-title>In-silico evidence for a two receptor based strategy of SARS-CoV-2</article-title><source>Front. Mol. Biosci.</source><year>2021</year><volume>8</volume><elocation-id>690655</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2021.690655</pub-id><pub-id pub-id-type="pmid">34179095</pub-id>
</element-citation></ref><ref id="B9-viruses-16-01836"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monti</surname><given-names>M.</given-names></name>
<name><surname>Milanetti</surname><given-names>E.</given-names></name>
<name><surname>Frans</surname><given-names>M.T.</given-names></name>
<name><surname>Miotto</surname><given-names>M.</given-names></name>
<name><surname>Di Rienzo</surname><given-names>L.</given-names></name>
<name><surname>Baranov</surname><given-names>M.V.</given-names></name>
<name><surname>Gosti</surname><given-names>G.</given-names></name>
<name><surname>Somavarapu</surname><given-names>A.K.</given-names></name>
<name><surname>Nagaraj</surname><given-names>M.</given-names></name>
<name><surname>Golbek</surname><given-names>T.W.</given-names></name>
</person-group><article-title>Two Receptor Binding Strategy of SARS-CoV-2 Is Mediated by Both the N-Terminal and Receptor-Binding Spike Domain</article-title><source>J. Phys. Chem. B</source><year>2024</year><volume>128</volume><fpage>451</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1021/acs.jpcb.3c06258</pub-id><pub-id pub-id-type="pmid">38190651</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01836"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Di Scala</surname><given-names>C.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
</person-group><article-title>Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>55</volume><fpage>105960</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105960</pub-id><pub-id pub-id-type="pmid">32251731</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01836"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
</person-group><article-title>Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2021</year><volume>538</volume><fpage>132</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.015</pub-id><pub-id pub-id-type="pmid">33097184</pub-id>
</element-citation></ref><ref id="B12-viruses-16-01836"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seyran</surname><given-names>M.</given-names></name>
<name><surname>Takayama</surname><given-names>K.</given-names></name>
<name><surname>Uversky</surname><given-names>V.N.</given-names></name>
<name><surname>Lundstrom</surname><given-names>K.</given-names></name>
<name><surname>Pal&#x000f9;</surname><given-names>G.</given-names></name>
<name><surname>Sherchan</surname><given-names>S.P.</given-names></name>
<name><surname>Attrish</surname><given-names>D.</given-names></name>
<name><surname>Rezaei</surname><given-names>N.</given-names></name>
<name><surname>Aljabali</surname><given-names>A.A.</given-names></name>
<name><surname>Ghosh</surname><given-names>S.</given-names></name>
</person-group><article-title>The structural basis of accelerated host cell entry by SARS-CoV-2</article-title><source>FEBS J.</source><year>2021</year><volume>288</volume><fpage>5010</fpage><lpage>5020</lpage><pub-id pub-id-type="doi">10.1111/febs.15651</pub-id><pub-id pub-id-type="pmid">33264497</pub-id>
</element-citation></ref><ref id="B13-viruses-16-01836"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lan</surname><given-names>J.</given-names></name>
<name><surname>Ge</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Shan</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Fan</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Shi</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
</person-group><article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>215</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id><pub-id pub-id-type="pmid">32225176</pub-id>
</element-citation></ref><ref id="B14-viruses-16-01836"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suryadevara</surname><given-names>N.</given-names></name>
<name><surname>Shrihari</surname><given-names>S.</given-names></name>
<name><surname>Gilchuk</surname><given-names>P.</given-names></name>
<name><surname>VanBlargan</surname><given-names>L.A.</given-names></name>
<name><surname>Binshtein</surname><given-names>E.</given-names></name>
<name><surname>Zost</surname><given-names>S.J.</given-names></name>
<name><surname>Nargi</surname><given-names>R.S.</given-names></name>
<name><surname>Sutton</surname><given-names>R.E.</given-names></name>
<name><surname>Winkler</surname><given-names>E.S.</given-names></name>
<name><surname>Chen</surname><given-names>E.C.</given-names></name>
</person-group><article-title>Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>2316</fpage><lpage>2331.e2315</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.03.029</pub-id><pub-id pub-id-type="pmid">33773105</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01836"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amanat</surname><given-names>F.</given-names></name>
<name><surname>Thapa</surname><given-names>M.</given-names></name>
<name><surname>Lei</surname><given-names>T.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.M.S.</given-names></name>
<name><surname>Adelsberg</surname><given-names>D.C.</given-names></name>
<name><surname>Carre&#x000f1;o</surname><given-names>J.M.</given-names></name>
<name><surname>Strohmeier</surname><given-names>S.</given-names></name>
<name><surname>Schmitz</surname><given-names>A.J.</given-names></name>
<name><surname>Zafar</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>J.Q.</given-names></name>
</person-group><article-title>SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>3936</fpage><lpage>3948.e3910</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.06.005</pub-id><pub-id pub-id-type="pmid">34192529</pub-id>
</element-citation></ref><ref id="B16-viruses-16-01836"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jaafar</surname><given-names>R.</given-names></name>
<name><surname>Boschi</surname><given-names>C.</given-names></name>
<name><surname>Aherfi</surname><given-names>S.</given-names></name>
<name><surname>Bancod</surname><given-names>A.</given-names></name>
<name><surname>Le Bideau</surname><given-names>M.</given-names></name>
<name><surname>Edouard</surname><given-names>S.</given-names></name>
<name><surname>Colson</surname><given-names>P.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
</person-group><article-title>High individual heterogeneity of neutralizing activities against the original strain and nine different variants of SARS-CoV-2</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>2177</elocation-id><pub-id pub-id-type="doi">10.3390/v13112177</pub-id><pub-id pub-id-type="pmid">34834983</pub-id>
</element-citation></ref><ref id="B17-viruses-16-01836"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
</person-group><article-title>Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal</article-title><source>Int. J. Antimicrob. Agents</source><year>2020</year><volume>56</volume><fpage>106020</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106020</pub-id></element-citation></ref><ref id="B18-viruses-16-01836"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gyselinck</surname><given-names>I.</given-names></name>
<name><surname>Janssens</surname><given-names>W.</given-names></name>
<name><surname>Verhamme</surname><given-names>P.</given-names></name>
<name><surname>Vos</surname><given-names>R.</given-names></name>
</person-group><article-title>Rationale for azithromycin in COVID-19: An overview of existing evidence</article-title><source>BMJ Open Respir. Res.</source><year>2021</year><volume>8</volume><fpage>e000806</fpage><pub-id pub-id-type="doi">10.1136/bmjresp-2020-000806</pub-id></element-citation></ref><ref id="B19-viruses-16-01836"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andreani</surname><given-names>J.</given-names></name>
<name><surname>Le Bideau</surname><given-names>M.</given-names></name>
<name><surname>Duflot</surname><given-names>I.</given-names></name>
<name><surname>Jardot</surname><given-names>P.</given-names></name>
<name><surname>Rolland</surname><given-names>C.</given-names></name>
<name><surname>Boxberger</surname><given-names>M.</given-names></name>
<name><surname>Wurtz</surname><given-names>N.</given-names></name>
<name><surname>Rolain</surname><given-names>J.-M.</given-names></name>
<name><surname>Colson</surname><given-names>P.</given-names></name>
<name><surname>La Scola</surname><given-names>B.</given-names></name>
</person-group><article-title>In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect</article-title><source>Microb. Pathog.</source><year>2020</year><volume>145</volume><fpage>104228</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020.104228</pub-id><pub-id pub-id-type="pmid">32344177</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01836"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caly</surname><given-names>L.</given-names></name>
<name><surname>Druce</surname><given-names>J.D.</given-names></name>
<name><surname>Catton</surname><given-names>M.G.</given-names></name>
<name><surname>Jans</surname><given-names>D.A.</given-names></name>
<name><surname>Wagstaff</surname><given-names>K.M.</given-names></name>
</person-group><article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title><source>Antivir. Res.</source><year>2020</year><volume>178</volume><fpage>104787</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><pub-id pub-id-type="pmid">32251768</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01836"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Low</surname><given-names>Z.Y.</given-names></name>
<name><surname>Yip</surname><given-names>A.J.W.</given-names></name>
<name><surname>Lal</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication</article-title><source>Biochim. Biophys. Acta-Mol. Basis Dis.</source><year>2022</year><volume>1868</volume><elocation-id>166294</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbadis.2021.166294</pub-id><pub-id pub-id-type="pmid">34687900</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01836"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Branda</surname><given-names>F.</given-names></name>
<name><surname>Ciccozzi</surname><given-names>M.</given-names></name>
<name><surname>Scarpa</surname><given-names>F.</given-names></name>
</person-group><article-title>Features of the SARS-CoV-2 KP. 3 variant mutations</article-title><source>Infect. Dis.</source><year>2024</year><volume>56</volume><fpage>894</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1080/23744235.2024.2385500</pub-id></element-citation></ref><ref id="B23-viruses-16-01836"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaku</surname><given-names>Y.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<name><surname>Kosugi</surname><given-names>Y.</given-names></name>
<name><surname>Okumura</surname><given-names>K.</given-names></name>
<name><surname>Yamasoba</surname><given-names>D.</given-names></name>
<name><surname>Uwamino</surname><given-names>Y.</given-names></name>
<name><surname>Kuramochi</surname><given-names>J.</given-names></name>
<name><surname>Sadamasu</surname><given-names>K.</given-names></name>
<name><surname>Yoshimura</surname><given-names>K.</given-names></name>
<name><surname>Asakura</surname><given-names>H.</given-names></name>
</person-group><article-title>Virological characteristics of the SARS-CoV-2 KP. 2 variant</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e416</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00298-6</pub-id><pub-id pub-id-type="pmid">38782005</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01836"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaku</surname><given-names>Y.</given-names></name>
<name><surname>Yo</surname><given-names>M.S.</given-names></name>
<name><surname>Tolentino</surname><given-names>J.E.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<name><surname>Okumura</surname><given-names>K.</given-names></name>
<name><surname>Ito</surname><given-names>J.</given-names></name>
<name><surname>Sato</surname><given-names>K.</given-names></name>
</person-group><article-title>Virological characteristics of the SARS-CoV-2 KP. 3, LB. 1, and KP. 2.3 variants</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e482</fpage><lpage>e483</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00415-8</pub-id><pub-id pub-id-type="pmid">38945150</pub-id>
</element-citation></ref><ref id="B25-viruses-16-01836"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shanmugaraj</surname><given-names>B.</given-names></name>
</person-group><article-title>Ever-evolving SARS-CoV-2: Latest variant KP. 2 is on the rise</article-title><source>Asian Pac. J. Trop. Med.</source><year>2024</year><volume>17</volume><fpage>241</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.4103/apjtm.apjtm_341_24</pub-id></element-citation></ref><ref id="B26-viruses-16-01836"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
<name><surname>Azzaz</surname><given-names>F.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
</person-group><article-title>Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks</article-title><source>J. Infect.</source><year>2021</year><volume>83</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2021.06.001</pub-id><pub-id pub-id-type="pmid">34089757</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01836"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>D.E.</given-names></name>
<name><surname>Chivian</surname><given-names>D.</given-names></name>
<name><surname>Baker</surname><given-names>D.</given-names></name>
</person-group><article-title>Protein structure prediction and analysis using the Robetta server</article-title><source>Nucleic Acids Res.</source><year>2004</year><volume>32</volume><fpage>W526</fpage><lpage>W531</lpage><pub-id pub-id-type="doi">10.1093/nar/gkh468</pub-id><pub-id pub-id-type="pmid">15215442</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01836"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guex</surname><given-names>N.</given-names></name>
<name><surname>Peitsch</surname><given-names>M.C.</given-names></name>
</person-group><article-title>SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling</article-title><source>Electrophoresis</source><year>1997</year><volume>18</volume><fpage>2714</fpage><lpage>2723</lpage><pub-id pub-id-type="doi">10.1002/elps.1150181505</pub-id><pub-id pub-id-type="pmid">9504803</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01836"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.</given-names></name>
<name><surname>Cha</surname><given-names>S.J.</given-names></name>
<name><surname>Choi</surname><given-names>H.-J.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
</person-group><article-title>Omega class glutathione S-transferase: Antioxidant enzyme in pathogenesis of neurodegenerative diseases</article-title><source>Oxidative Med. Cell. Longev.</source><year>2017</year><volume>2017</volume><fpage>5049532</fpage><pub-id pub-id-type="doi">10.1155/2017/5049532</pub-id></element-citation></ref><ref id="B30-viruses-16-01836"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Tsuji</surname><given-names>M.</given-names></name>
</person-group><source>Docking Study with HyperChem, Revision G1</source><publisher-name>Institute of Molecular Function</publisher-name><publisher-loc>Saitama, Japan</publisher-loc><year>2015</year></element-citation></ref><ref id="B31-viruses-16-01836"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsuji</surname><given-names>M.</given-names></name>
<name><surname>Shudo</surname><given-names>K.</given-names></name>
<name><surname>Kagechika</surname><given-names>H.</given-names></name>
</person-group><article-title>Docking simulations suggest that all-trans retinoic acid could bind to retinoid X receptors</article-title><source>J. Comput.-Aided Mol. Des.</source><year>2015</year><volume>29</volume><fpage>975</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1007/s10822-015-9869-9</pub-id><pub-id pub-id-type="pmid">26384496</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01836"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Tsuji</surname><given-names>M.</given-names></name>
</person-group><source>Homology Modeling Professional for HyperChem, Revision G1</source><publisher-name>Institute of Molecular Function</publisher-name><publisher-loc>Saitama, Japan</publisher-loc><year>2015</year></element-citation></ref><ref id="B33-viruses-16-01836"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srinivasu</surname><given-names>N.</given-names></name>
<name><surname>Babu</surname><given-names>M.N.</given-names></name>
<name><surname>Rao</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Energy Minimization of CDK2 bound ligands: A Computational Approach</article-title><source>Int. J. Eng. Res. Appl.</source><year>2012</year><volume>2</volume><fpage>1884</fpage><lpage>1887</lpage></element-citation></ref><ref id="B34-viruses-16-01836"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomsen</surname><given-names>R.</given-names></name>
<name><surname>Christensen</surname><given-names>M.H.</given-names></name>
</person-group><article-title>MolDock: A new technique for high-accuracy molecular docking</article-title><source>J. Med. Chem.</source><year>2006</year><volume>49</volume><fpage>3315</fpage><lpage>3321</lpage><pub-id pub-id-type="doi">10.1021/jm051197e</pub-id><pub-id pub-id-type="pmid">16722650</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01836"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakur</surname><given-names>G.</given-names></name>
<name><surname>Micic</surname><given-names>M.</given-names></name>
<name><surname>Leblanc</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Surface chemistry of Alzheimer&#x02019;s disease: A Langmuir monolayer approach</article-title><source>Colloids Surf. B Biointerfaces</source><year>2009</year><volume>74</volume><fpage>436</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2009.07.043</pub-id><pub-id pub-id-type="pmid">19726167</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01836"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elderdfi</surname><given-names>M.</given-names></name>
<name><surname>Sikorski</surname><given-names>A.F.</given-names></name>
</person-group><article-title>Langmuir-monolayer methodologies for characterizing protein-lipid interactions</article-title><source>Chem. Phys. Lipids</source><year>2018</year><volume>212</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.chemphyslip.2018.01.008</pub-id><pub-id pub-id-type="pmid">29360431</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01836"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diociaiuti</surname><given-names>M.</given-names></name>
<name><surname>Giordani</surname><given-names>C.</given-names></name>
<name><surname>Kamel</surname><given-names>G.S.</given-names></name>
<name><surname>Brasili</surname><given-names>F.</given-names></name>
<name><surname>Sennato</surname><given-names>S.</given-names></name>
<name><surname>Bombelli</surname><given-names>C.</given-names></name>
<name><surname>Meneses</surname><given-names>K.Y.</given-names></name>
<name><surname>Giraldo</surname><given-names>M.A.</given-names></name>
<name><surname>Bordi</surname><given-names>F.</given-names></name>
</person-group><article-title>Monosialoganglioside-GM1 triggers binding of the amyloid-protein salmon calcitonin to a Langmuir membrane model mimicking the occurrence of lipid-rafts</article-title><source>Biochem. Biophys. Rep.</source><year>2016</year><volume>8</volume><fpage>365</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.bbrep.2016.10.005</pub-id><pub-id pub-id-type="pmid">28955978</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01836"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Scala</surname><given-names>C.</given-names></name>
<name><surname>Fantini</surname><given-names>J.</given-names></name>
</person-group><article-title>Hybrid In Silico/In Vitro Approaches for the Identification of Functional Cholesterol-Binding Domains in Membrane Proteins</article-title><source>Methods Mol. Biol.</source><year>2017</year><volume>1583</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-6875-6_2</pub-id><pub-id pub-id-type="pmid">28205163</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01836"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ayodele</surname><given-names>P.F.</given-names></name>
<name><surname>Bamigbade</surname><given-names>A.</given-names></name>
<name><surname>Bamigbade</surname><given-names>O.O.</given-names></name>
<name><surname>Adeniyi</surname><given-names>I.A.</given-names></name>
<name><surname>Tachin</surname><given-names>E.S.</given-names></name>
<name><surname>Seweje</surname><given-names>A.J.</given-names></name>
<name><surname>Farohunbi</surname><given-names>S.T.</given-names></name>
</person-group><article-title>Illustrated Procedure to Perform Molecular Docking Using PyRx and Biovia Discovery Studio Visualizer: A Case Study of 10kt With Atropine</article-title><source>Prog. Drug Discov. Biomed. Sci.</source><year>2023</year><volume>6</volume><fpage>1</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.36877/pddbs.a0000424</pub-id></element-citation></ref><ref id="B40-viruses-16-01836"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ewing</surname><given-names>T.J.A.</given-names></name>
<name><surname>Makino</surname><given-names>S.</given-names></name>
<name><surname>Skillman</surname><given-names>A.G.</given-names></name>
<name><surname>Kuntz</surname><given-names>I.D.</given-names></name>
</person-group><article-title>DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases</article-title><source>J. Comput.-Aided Mol. Des.</source><year>2001</year><volume>15</volume><fpage>411</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1023/A:1011115820450</pub-id><pub-id pub-id-type="pmid">11394736</pub-id>
</element-citation></ref><ref id="B41-viruses-16-01836"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trott</surname><given-names>O.</given-names></name>
<name><surname>Olson</surname><given-names>A.J.</given-names></name>
</person-group><article-title>AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>J. Comput. Chem.</source><year>2010</year><volume>31</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01836"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paggi</surname><given-names>J.M.</given-names></name>
<name><surname>Pandit</surname><given-names>A.</given-names></name>
<name><surname>Dror</surname><given-names>R.O.</given-names></name>
</person-group><article-title>The Art and Science of Molecular Docking</article-title><source>Annu. Rev. Biochem.</source><year>2024</year><volume>93</volume><fpage>389</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-030222-120000</pub-id><pub-id pub-id-type="pmid">38594926</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01836"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.C.</given-names></name>
</person-group><article-title>Beware of docking!</article-title><source>Trends Pharmacol. Sci.</source><year>2015</year><volume>36</volume><fpage>78</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2014.12.001</pub-id><pub-id pub-id-type="pmid">25543280</pub-id>
</element-citation></ref><ref id="B44-viruses-16-01836"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buttenschoen</surname><given-names>M.</given-names></name>
<name><surname>Morris</surname><given-names>G.M.</given-names></name>
<name><surname>Deane</surname><given-names>C.M.</given-names></name>
</person-group><article-title>PoseBusters: AI-based docking methods fail to generate physically valid poses or generalise to novel sequences</article-title><source>Chem. Sci.</source><year>2024</year><volume>15</volume><fpage>3130</fpage><lpage>3139</lpage><pub-id pub-id-type="doi">10.1039/D3SC04185A</pub-id><pub-id pub-id-type="pmid">38425520</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01836"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarkar</surname><given-names>A.</given-names></name>
<name><surname>Concilio</surname><given-names>S.</given-names></name>
<name><surname>Sessa</surname><given-names>L.</given-names></name>
<name><surname>Marrafino</surname><given-names>F.</given-names></name>
<name><surname>Piotto</surname><given-names>S.</given-names></name>
</person-group><article-title>Advancements and novel approaches in modified autodock vina algorithms for enhanced molecular docking</article-title><source>Results Chem.</source><year>2024</year><volume>7</volume><fpage>101319</fpage><pub-id pub-id-type="doi">10.1016/j.rechem.2024.101319</pub-id></element-citation></ref><ref id="B46-viruses-16-01836"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Wong</surname><given-names>C.F.</given-names></name>
<name><surname>Wheeler</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Flexible protein-flexible ligand docking with disrupted velocity simulated annealing</article-title><source>Proteins</source><year>2008</year><volume>71</volume><fpage>440</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1002/prot.21781</pub-id><pub-id pub-id-type="pmid">17957770</pub-id>
</element-citation></ref><ref id="B47-viruses-16-01836"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Changeux</surname><given-names>J.-P.</given-names></name>
<name><surname>Edelstein</surname><given-names>S.</given-names></name>
</person-group><article-title>Conformational selection or induced fit? 50 years of debate resolved</article-title><source>F1000 Biol. Rep.</source><year>2011</year><volume>3</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.3410/B3-19</pub-id><pub-id pub-id-type="pmid">21941598</pub-id>
</element-citation></ref><ref id="B48-viruses-16-01836"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gianni</surname><given-names>S.</given-names></name>
<name><surname>Dogan</surname><given-names>J.</given-names></name>
<name><surname>Jemth</surname><given-names>P.</given-names></name>
</person-group><article-title>Distinguishing induced fit from conformational selection</article-title><source>Biophys. Chem.</source><year>2014</year><volume>189</volume><fpage>33</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.bpc.2014.03.003</pub-id><pub-id pub-id-type="pmid">24747333</pub-id>
</element-citation></ref><ref id="B49-viruses-16-01836"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wlodarski</surname><given-names>T.</given-names></name>
<name><surname>Zagrovic</surname><given-names>B.</given-names></name>
</person-group><article-title>Conformational selection and induced fit mechanism underlie specificity in noncovalent interactions with ubiquitin</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>19346</fpage><lpage>19351</lpage><pub-id pub-id-type="doi">10.1073/pnas.0906966106</pub-id><pub-id pub-id-type="pmid">19887638</pub-id>
</element-citation></ref><ref id="B50-viruses-16-01836"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Islas</surname><given-names>&#x000c1;.A.</given-names></name>
<name><surname>Scior</surname><given-names>T.</given-names></name>
</person-group><article-title>Allosteric Binding of MDMA to the Human Serotonin Transporter (hSERT) via Ensemble Binding Space Analysis with &#x00394;G Calculations, Induced Fit Docking and Monte Carlo Simulations</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>2977</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27092977</pub-id><pub-id pub-id-type="pmid">35566327</pub-id>
</element-citation></ref><ref id="B51-viruses-16-01836"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uversky</surname><given-names>V.N.</given-names></name>
</person-group><article-title>Intrinsically disordered proteins and their environment: Effects of strong denaturants, temperature, pH, counter ions, membranes, binding partners, osmolytes, and macromolecular crowding</article-title><source>Protein J.</source><year>2009</year><volume>28</volume><fpage>305</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1007/s10930-009-9201-4</pub-id><pub-id pub-id-type="pmid">19768526</pub-id>
</element-citation></ref><ref id="B52-viruses-16-01836"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uversky</surname><given-names>V.N.</given-names></name>
</person-group><article-title>Intrinsically disordered proteins and novel strategies for drug discovery</article-title><source>Expert Opin. Drug Discov.</source><year>2012</year><volume>7</volume><fpage>475</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1517/17460441.2012.686489</pub-id><pub-id pub-id-type="pmid">22559227</pub-id>
</element-citation></ref><ref id="B53-viruses-16-01836"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uversky</surname><given-names>V.N.</given-names></name>
</person-group><article-title>Introduction to intrinsically disordered proteins (IDPs)</article-title><source>Chem. Rev.</source><year>2014</year><volume>114</volume><fpage>6557</fpage><lpage>6560</lpage><pub-id pub-id-type="doi">10.1021/cr500288y</pub-id><pub-id pub-id-type="pmid">25004990</pub-id>
</element-citation></ref><ref id="B54-viruses-16-01836"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>N.</given-names></name>
<name><surname>Kalyanaraman</surname><given-names>C.</given-names></name>
<name><surname>Bernacki</surname><given-names>K.</given-names></name>
<name><surname>Jacobson</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Molecular mechanics methods for predicting protein-ligand binding</article-title><source>Phys. Chem. Chem. Phys. PCCP</source><year>2006</year><volume>8</volume><fpage>5166</fpage><lpage>5177</lpage><pub-id pub-id-type="doi">10.1039/B608269F</pub-id><pub-id pub-id-type="pmid">17203140</pub-id>
</element-citation></ref><ref id="B55-viruses-16-01836"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Introduction to molecular dynamics simulation</article-title><source>Comput. Soft Matter Synth. Polym. Proteins</source><year>2004</year><volume>23</volume><fpage>1</fpage><lpage>28</lpage></element-citation></ref><ref id="B56-viruses-16-01836"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sokkar</surname><given-names>P.</given-names></name>
<name><surname>Mohandass</surname><given-names>S.</given-names></name>
<name><surname>Ramachandran</surname><given-names>M.</given-names></name>
</person-group><article-title>Multiple templates-based homology modeling enhances structure quality of AT1 receptor: Validation by molecular dynamics and antagonist docking</article-title><source>J. Mol. Model.</source><year>2011</year><volume>17</volume><fpage>1565</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1007/s00894-010-0860-z</pub-id><pub-id pub-id-type="pmid">20924625</pub-id>
</element-citation></ref><ref id="B57-viruses-16-01836"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>H.</given-names></name>
<name><surname>Caflisch</surname><given-names>A.</given-names></name>
</person-group><article-title>Molecular dynamics in drug design</article-title><source>Eur. J. Med. Chem.</source><year>2015</year><volume>91</volume><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.08.004</pub-id><pub-id pub-id-type="pmid">25108504</pub-id>
</element-citation></ref><ref id="B58-viruses-16-01836"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>H.</given-names></name>
<name><surname>Bliznyuk</surname><given-names>A.A.</given-names></name>
<name><surname>Gready</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Combining docking and molecular dynamic simulations in drug design</article-title><source>Med. Res. Rev.</source><year>2006</year><volume>26</volume><fpage>531</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1002/med.20067</pub-id><pub-id pub-id-type="pmid">16758486</pub-id>
</element-citation></ref><ref id="B59-viruses-16-01836"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borcik</surname><given-names>C.G.</given-names></name>
<name><surname>Eason</surname><given-names>I.R.</given-names></name>
<name><surname>Yekefallah</surname><given-names>M.</given-names></name>
<name><surname>Amani</surname><given-names>R.</given-names></name>
<name><surname>Han</surname><given-names>R.</given-names></name>
<name><surname>Vanderloop</surname><given-names>B.H.</given-names></name>
<name><surname>Wylie</surname><given-names>B.J.</given-names></name>
</person-group><article-title>A cholesterol dimer stabilizes the inactivated state of an inward-rectifier Potassium Channel</article-title><source>Angew. Chem. Int. Ed.</source><year>2022</year><volume>61</volume><fpage>e202112232</fpage><pub-id pub-id-type="doi">10.1002/anie.202112232</pub-id></element-citation></ref><ref id="B60-viruses-16-01836"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sinha</surname><given-names>S.</given-names></name>
<name><surname>Tam</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Applications of molecular dynamics simulation in protein study</article-title><source>Membranes</source><year>2022</year><volume>12</volume><elocation-id>844</elocation-id><pub-id pub-id-type="doi">10.3390/membranes12090844</pub-id><pub-id pub-id-type="pmid">36135863</pub-id>
</element-citation></ref><ref id="B61-viruses-16-01836"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kharche</surname><given-names>S.A.</given-names></name>
<name><surname>Sengupta</surname><given-names>D.</given-names></name>
</person-group><article-title>Dynamic protein interfaces and conformational landscapes of membrane protein complexes</article-title><source>Curr. Opin. Struct. Biol.</source><year>2020</year><volume>61</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2020.01.001</pub-id><pub-id pub-id-type="pmid">32036279</pub-id>
</element-citation></ref><ref id="B62-viruses-16-01836"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borges-Ara&#x000fa;jo</surname><given-names>L.</given-names></name>
<name><surname>Patmanidis</surname><given-names>I.</given-names></name>
<name><surname>Singh</surname><given-names>A.P.</given-names></name>
<name><surname>Santos</surname><given-names>L.H.</given-names></name>
<name><surname>Sieradzan</surname><given-names>A.K.</given-names></name>
<name><surname>Vanni</surname><given-names>S.</given-names></name>
<name><surname>Czaplewski</surname><given-names>C.</given-names></name>
<name><surname>Pantano</surname><given-names>S.</given-names></name>
<name><surname>Shinoda</surname><given-names>W.</given-names></name>
<name><surname>Monticelli</surname><given-names>L.</given-names></name>
</person-group><article-title>Pragmatic coarse-graining of proteins: Models and applications</article-title><source>J. Chem. Theory Comput.</source><year>2023</year><volume>19</volume><fpage>7112</fpage><lpage>7135</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.3c00733</pub-id><pub-id pub-id-type="pmid">37788237</pub-id>
</element-citation></ref><ref id="B63-viruses-16-01836"><label>63.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Nocedal</surname><given-names>J.</given-names></name>
<name><surname>Wright</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Conjugate gradient methods</article-title><source>Numerical Optimization</source><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2006</year><fpage>101</fpage><lpage>134</lpage></element-citation></ref><ref id="B64-viruses-16-01836"><label>64.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Andrei</surname><given-names>N.</given-names></name>
</person-group><article-title>Conjugate Gradient Methods</article-title><source>Modern Numerical Nonlinear Optimization</source><person-group person-group-type="editor">
<name><surname>Andrei</surname><given-names>N.</given-names></name>
</person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2022</year><fpage>169</fpage><lpage>260</lpage></element-citation></ref><ref id="B65-viruses-16-01836"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grippo</surname><given-names>L.</given-names></name>
<name><surname>Lucidi</surname><given-names>S.</given-names></name>
</person-group><article-title>A globally convergent version of the Polak-Ribiere conjugate gradient method</article-title><source>Math. Program.</source><year>1997</year><volume>78</volume><fpage>375</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1007/BF02614362</pub-id></element-citation></ref><ref id="B66-viruses-16-01836"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khoda</surname><given-names>K.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Storey</surname><given-names>C.</given-names></name>
</person-group><article-title>Generalized Polak-Ribiere algorithm</article-title><source>J. Optim. Theory Appl.</source><year>1992</year><volume>75</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1007/BF00941472</pub-id></element-citation></ref><ref id="B67-viruses-16-01836"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maresca</surname><given-names>M.</given-names></name>
<name><surname>Derghal</surname><given-names>A.</given-names></name>
<name><surname>Caravagna</surname><given-names>C.</given-names></name>
<name><surname>Dudin</surname><given-names>S.</given-names></name>
<name><surname>Fantini</surname><given-names>J.</given-names></name>
</person-group><article-title>Controlled aggregation of adenine by sugars: Physicochemical studies, molecular modelling simulations of sugar-aromatic CH-pi stacking interactions, and biological significance</article-title><source>Phys. Chem. Chem. Phys. PCCP</source><year>2008</year><volume>10</volume><fpage>2792</fpage><lpage>2800</lpage><pub-id pub-id-type="doi">10.1039/b802594k</pub-id><pub-id pub-id-type="pmid">18464996</pub-id>
</element-citation></ref><ref id="B68-viruses-16-01836"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tronrud</surname><given-names>D.E.</given-names></name>
</person-group><article-title>Introduction to macromolecular refinement</article-title><source>Acta Crystallogr. Sect. D Biol. Crystallogr.</source><year>2004</year><volume>60</volume><fpage>2156</fpage><lpage>2168</lpage><pub-id pub-id-type="doi">10.1107/S090744490402356X</pub-id><pub-id pub-id-type="pmid">15572769</pub-id>
</element-citation></ref><ref id="B69-viruses-16-01836"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Scala</surname><given-names>C.</given-names></name>
<name><surname>Troadec</surname><given-names>J.D.</given-names></name>
<name><surname>Leli&#x000e8;vre</surname><given-names>C.</given-names></name>
<name><surname>Garmy</surname><given-names>N.</given-names></name>
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
</person-group><article-title>Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer &#x003b2;-amyloid peptide</article-title><source>J. Neurochem.</source><year>2014</year><volume>128</volume><fpage>186</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1111/jnc.12390</pub-id><pub-id pub-id-type="pmid">23919567</pub-id>
</element-citation></ref><ref id="B70-viruses-16-01836"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choudhury</surname><given-names>A.</given-names></name>
<name><surname>Das</surname><given-names>N.C.</given-names></name>
<name><surname>Patra</surname><given-names>R.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>M.</given-names></name>
<name><surname>Ghosh</surname><given-names>P.</given-names></name>
<name><surname>Patra</surname><given-names>B.C.</given-names></name>
<name><surname>Mukherjee</surname><given-names>S.</given-names></name>
</person-group><article-title>Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: An in silico approach</article-title><source>Future Virol.</source><year>2021</year><volume>16</volume><fpage>277</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.2217/fvl-2020-0342</pub-id></element-citation></ref><ref id="B71-viruses-16-01836"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aminpour</surname><given-names>M.</given-names></name>
<name><surname>Cannariato</surname><given-names>M.</given-names></name>
<name><surname>Preto</surname><given-names>J.</given-names></name>
<name><surname>Safaeeardebili</surname><given-names>M.E.</given-names></name>
<name><surname>Moracchiato</surname><given-names>A.</given-names></name>
<name><surname>Doria</surname><given-names>D.</given-names></name>
<name><surname>Donato</surname><given-names>F.</given-names></name>
<name><surname>Zizzi</surname><given-names>E.A.</given-names></name>
<name><surname>Deriu</surname><given-names>M.A.</given-names></name>
<name><surname>Scheim</surname><given-names>D.E.</given-names></name>
</person-group><article-title>In silico analysis of the multi-targeted mode of action of ivermectin and related compounds</article-title><source>Computation</source><year>2022</year><volume>10</volume><elocation-id>51</elocation-id><pub-id pub-id-type="doi">10.3390/computation10040051</pub-id></element-citation></ref><ref id="B72-viruses-16-01836"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>X.-L.</given-names></name>
</person-group><article-title>The role of cell surface sialic acids for SARS-CoV-2 infection</article-title><source>Glycobiology</source><year>2021</year><volume>31</volume><fpage>1245</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwab032</pub-id><pub-id pub-id-type="pmid">33909065</pub-id>
</element-citation></ref><ref id="B73-viruses-16-01836"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Gaetano</surname><given-names>S.</given-names></name>
<name><surname>Capasso</surname><given-names>D.</given-names></name>
<name><surname>Delre</surname><given-names>P.</given-names></name>
<name><surname>Pirone</surname><given-names>L.</given-names></name>
<name><surname>Saviano</surname><given-names>M.</given-names></name>
<name><surname>Pedone</surname><given-names>E.</given-names></name>
<name><surname>Mangiatordi</surname><given-names>G.F.</given-names></name>
</person-group><article-title>More Is Always Better Than One: The N-Terminal Domain of the Spike Protein as Another Emerging Target for Hampering the SARS-CoV-2 Attachment to Host Cells</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>6462</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22126462</pub-id><pub-id pub-id-type="pmid">34208755</pub-id>
</element-citation></ref><ref id="B74-viruses-16-01836"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boschi</surname><given-names>C.</given-names></name>
<name><surname>Scheim</surname><given-names>D.E.</given-names></name>
<name><surname>Bancod</surname><given-names>A.</given-names></name>
<name><surname>Militello</surname><given-names>M.</given-names></name>
<name><surname>Bideau</surname><given-names>M.L.</given-names></name>
<name><surname>Colson</surname><given-names>P.</given-names></name>
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Scola</surname><given-names>B.L.</given-names></name>
</person-group><article-title>SARS-CoV-2 spike protein induces hemagglutination: Implications for COVID-19 morbidities and therapeutics and for vaccine adverse effects</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>15480</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232415480</pub-id><pub-id pub-id-type="pmid">36555121</pub-id>
</element-citation></ref><ref id="B75-viruses-16-01836"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
<name><surname>Yahi</surname><given-names>N.</given-names></name>
<name><surname>Colson</surname><given-names>P.</given-names></name>
<name><surname>Chahinian</surname><given-names>H.</given-names></name>
<name><surname>La Scola</surname><given-names>B.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>The puzzling mutational landscape of the SARS-2-variant Omicron</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>2019</fpage><lpage>2025</lpage><pub-id pub-id-type="doi">10.1002/jmv.27577</pub-id><pub-id pub-id-type="pmid">34997962</pub-id>
</element-citation></ref><ref id="B76-viruses-16-01836"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
</person-group><article-title>Lipid rafts and human diseases: Why we need to target gangliosides</article-title><source>FEBS Open Bio</source><year>2023</year><volume>13</volume><fpage>1636</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.13612</pub-id><pub-id pub-id-type="pmid">37052878</pub-id>
</element-citation></ref><ref id="B77-viruses-16-01836"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fantini</surname><given-names>J.</given-names></name>
</person-group><article-title>Fundamental Mechanisms in Membrane Receptology: Old Paradigms, New Concepts and Perspectives</article-title><source>Receptors</source><year>2024</year><volume>3</volume><fpage>107</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.3390/receptors3010006</pub-id></element-citation></ref><ref id="B78-viruses-16-01836"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Bakker</surname><given-names>A.S.</given-names></name>
<name><surname>Narimatsu</surname><given-names>Y.</given-names></name>
<name><surname>van Kuppeveld</surname><given-names>F.J.</given-names></name>
<name><surname>Clausen</surname><given-names>H.</given-names></name>
<name><surname>de Haan</surname><given-names>C.A.</given-names></name>
<name><surname>de Vries</surname><given-names>E.</given-names></name>
</person-group><article-title>H3N2 influenza A virus gradually adapts to human-type receptor binding and entry specificity after the start of the 1968 pandemic</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2023</year><volume>120</volume><fpage>e2304992120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2304992120</pub-id><pub-id pub-id-type="pmid">37467282</pub-id>
</element-citation></ref><ref id="B79-viruses-16-01836"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Str&#x000f6;h</surname><given-names>L.J.</given-names></name>
<name><surname>Nagarathinam</surname><given-names>K.</given-names></name>
<name><surname>Krey</surname><given-names>T.</given-names></name>
</person-group><article-title>Conformational flexibility in the CD81-binding site of the hepatitis C virus glycoprotein E2</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>1396</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01396</pub-id><pub-id pub-id-type="pmid">29967619</pub-id>
</element-citation></ref><ref id="B80-viruses-16-01836"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghoula</surname><given-names>M.</given-names></name>
<name><surname>Naceri</surname><given-names>S.</given-names></name>
<name><surname>Sitruk</surname><given-names>S.</given-names></name>
<name><surname>Flatters</surname><given-names>D.</given-names></name>
<name><surname>Moroy</surname><given-names>G.</given-names></name>
<name><surname>Camproux</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2023</year><volume>21</volume><fpage>2339</fpage><lpage>2351</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2023.03.029</pub-id><pub-id pub-id-type="pmid">36998674</pub-id>
</element-citation></ref><ref id="B81-viruses-16-01836"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zaidi</surname><given-names>A.K.</given-names></name>
<name><surname>Dehgani-Mobaraki</surname><given-names>P.</given-names></name>
</person-group><article-title>The mechanisms of action of ivermectin against SARS-CoV-2&#x02014;An extensive review</article-title><source>J. Antibiot.</source><year>2022</year><volume>75</volume><fpage>60</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/s41429-021-00491-6</pub-id></element-citation></ref><ref id="B82-viruses-16-01836"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scheim</surname><given-names>D.E.</given-names></name>
</person-group><article-title>A deadly embrace: Hemagglutination mediated by SARS-CoV-2 spike protein at its 22 N-glycosylation sites, red blood cell surface sialoglycoproteins, and antibody</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>2558</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23052558</pub-id><pub-id pub-id-type="pmid">35269703</pub-id>
</element-citation></ref><ref id="B83-viruses-16-01836"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scheim</surname><given-names>D.E.</given-names></name>
<name><surname>Vottero</surname><given-names>P.</given-names></name>
<name><surname>Santin</surname><given-names>A.D.</given-names></name>
<name><surname>Hirsh</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Sialylated glycan bindings from SARS-CoV-2 spike protein to blood and endothelial cells govern the severe morbidities of COVID-19</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>17039</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242317039</pub-id><pub-id pub-id-type="pmid">38069362</pub-id>
</element-citation></ref><ref id="B84-viruses-16-01836"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dima</surname><given-names>F.</given-names></name>
<name><surname>Salvagno</surname><given-names>G.L.</given-names></name>
<name><surname>Lippi</surname><given-names>G.</given-names></name>
</person-group><article-title>Effects of recombinant SARS-CoV-2 spike protein variants on red blood cells parameters and red blood cell distribution width</article-title><source>Biomed. J.</source><year>2024</year><volume>47</volume><elocation-id>100787</elocation-id><pub-id pub-id-type="doi">10.1016/j.bj.2024.100787</pub-id><pub-id pub-id-type="pmid">39251135</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01836-f001"><label>Figure 1</label><caption><p>Mutational landscape of SARS-CoV-2 spike proteins. The electrostatic surface potential of the protein is visible by transparency. Amino acid residues are represented in atomic spheres and colored according to the amino acid type (e.g., acidic residues are colored in red). Deletions and insertions are indicated by an asterisk in a yellow disk. Legend: Wuhan, B.1; Alpha, B.1.7; Delta, B.1.617.2.</p></caption><graphic xlink:href="viruses-16-01836-g001" position="float"/></fig><fig position="float" id="viruses-16-01836-f002"><label>Figure 2</label><caption><p>Characterization of an ivermectin binding site on the NTD of the B.1 spike protein. Left panel: electrostatic surface potential of the spike protein (electronegative areas in red, electropositive areas in blue, neutral areas in white). NTD, N-terminal domain; RBD, receptor binding domain; IVM, ivermectin (atomic spheres colored in yellow). Central panel: trimeric spike protein, each subunit in a different color (cyan, green, and yellow), and ivermectin bound to each NTD (in atoms colors, with oxygen in red). In this prefusion conformation, the central RBDs are still masked and not available for ACE2. Right panel: key amino acid residues of the B.1 NTD determining the ivermectin binding site. For clarity, Q14 is not represented. Ivermectin is represented in atomic spheres and colored yellow. Its chemical structure is shown in the central inset.</p></caption><graphic xlink:href="viruses-16-01836-g002" position="float"/></fig><fig position="float" id="viruses-16-01836-f003"><label>Figure 3</label><caption><p>Flexible docking of ivermectin (IVM) on the spike NTD. (<bold>A</bold>) Movements of the secondary structure of the spike protein during the docking of ivermectin (IVM) on the NTD of the Wuhan spike protein. The initial secondary structure is colored blue, and the final structure is grey. The movements involving the ivermectin binding site are indicated by arrows. Long-range conformational changes are indicated by asterisks. (<bold>B</bold>) Loss of a part of a beta-strand during the simulations (arrow). The upper sequence corresponds to the initial structure with amino acid residues 179-LEG-181 belonging to a beta-strand, and the lower sequence to the final structure with the same amino acids excluded from the beta-strand. (<bold>C</bold>) Flexibility of amino acid chains upon docking (arrows). Movements of the secondary structure are indicated by an asterisk. R158 belongs to the ivermectin binding site but not F140.</p></caption><graphic xlink:href="viruses-16-01836-g003" position="float"/></fig><fig position="float" id="viruses-16-01836-f004"><label>Figure 4</label><caption><p>Ivermectin occupies a large part of the GM1-binding domain of the NTD. (<bold>A</bold>) Structural models of the NTD in complex with ivermectin (IVM) or a GM1 raft. Ivermectin is represented in atomic yellow spheres. The spike protein (Wuhan strain) and the GM1 raft are represented in electrostatic surface potential (hence mostly red for the GM1 raft, i.e., electronegative, and red/blue/white for the spike protein, as in <xref rid="viruses-16-01836-f002" ref-type="fig">Figure 2</xref>). The insets show the molecular complexes at higher magnification. Ivermectin is superposed to the GM1 raft to visualize the respective locations of both binding sites. (<bold>B</bold>) Superposition of the ivermectin (IVM, atomic yellow spheres) and GM1 raft (light pink surface rendition) binding sites on the spike NTD. The main amino acid residues involved in both binding sites are Q14, E156, R158, G252, D253, and R246. F157 is close, but it contributes only marginally to the binding of ivermectin. Residues indicated with a blue disk are critical for GM1 binding but outside the ivermectin binding site.</p></caption><graphic xlink:href="viruses-16-01836-g004" position="float"/></fig><fig position="float" id="viruses-16-01836-f005"><label>Figure 5</label><caption><p>Structural evolution of the ivermectin binding site on the NTD of the alpha, delta, and omicron variants. Upper panels: For each variant, the whole spike protein is shown in complex with ivermectin (represented in atomic spheres and colored in yellow). The spike protein is represented as in <xref rid="viruses-16-01836-f002" ref-type="fig">Figure 2</xref> (electrostatic surface potential). Lower panels: magnification of the NTD&#x02013;ivermectin complex illustrating the different modes of interaction of the drug according to the variant studied. Note that the NTD varies both in global shape and in electrostatic surface potential.</p></caption><graphic xlink:href="viruses-16-01836-g005" position="float"/></fig><fig position="float" id="viruses-16-01836-f006"><label>Figure 6</label><caption><p>Different conformations adopted by ivermectin in complex with each NTD variant. The molecule is represented in atomic spheres superimposed with a slightly transparent surface colored in yellow. Note that the molecule can adopt various &#x0201c;octopus-like&#x0201d; conformations (a central head and lateral arms) according to the spike protein with which it interacts. An animation (<xref rid="app1-viruses-16-01836" ref-type="app">Figure S2</xref>) with a superposition of all these conformers illustrates the high flexibility of ivermectin.</p></caption><graphic xlink:href="viruses-16-01836-g006" position="float"/></fig><fig position="float" id="viruses-16-01836-f007"><label>Figure 7</label><caption><p>The interaction of trimeric spike proteins with a monolayer ganglioside GM1 is inhibited by ivermectin. Left panel: kinetics of interaction of the indicated spike protein trimer (Wuhan, B.1; Alpha; Delta; and Omicron BA.1, tested at a final concentration of 5 pM) with a GM1 monolayer prepared at an initial pressure of 20 mN&#x000b7;m<sup>&#x02212;1</sup>. For clarity, a representative experiment performed on the same days with the 4 spike proteins is shown (the experiment was repeated three times with similar results). Rabbit IgG (r-IgG) was used as a negative control. Right panel: preincubation of the Wuhan B.1 and Alpha spike proteins (5 pM) with ivermectin (800 nM) resulted in a reproducible inhibition of the initial velocity of the interaction calculated during the first 10 min of the incubation with the monolayer (calibrated against a control experiment with the ivermectin vehicle only considered as 100%). Results are expressed as mean % of inhibition &#x000b1; SD (<italic toggle="yes">n</italic> = 3).</p></caption><graphic xlink:href="viruses-16-01836-g007" position="float"/></fig></floats-group></article>